IP Library Granted Patent US 11,365,437
Granted Patent B2
US 11,365,437 · App. 15/936,293 · Granted Jun 21, 2022

Quantitative assessment for cap efficiency of messenger RNA

Inventors: Michael Heartlein (Cambridge, MA); Frank DeRosa (Cambridge, MA); Anusha Dias (Cambridge, MA)
Assignee: Translate Bio, Inc.
C12Q1/68C07K14/505C12N9/0069C12Q1/6823C12Y113/12007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,365,437
App. No.
15/936,293
Granted
Jun 21, 2022
Kind
B2
Abstract

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps.

Claims (33)

1. A method of quantifying mRNA capping efficiency, the method comprising:

(1) providing an mRNA sample comprising capped mRNA and uncapped mRNA;

(2) annealing the mRNA sample with a DNA oligonucleotide of about 10-20 bases in length, complementary to a sequence in the 5′ untranslated region of the mRNA, wherein the first base of the DNA oligonucleotide binds within 5 bases from the cap or uncapped penultimate base of mRNA under conditions that permit the DNA oligonucleotide to anneal to the sequence and form a DNA/RNA hybrid;

(3) introducing to the sample one or more nucleases that selectively degrade the DNA/RNA hybrid, resulting in capped and uncapped fragments comprising no more than 5 bases of the mRNA, wherein the one or more nucleases is nuclease S1 or RNAse H;

(4) applying the capped and uncapped fragments to a chromatographic column, thereby separating the capped and uncapped fragments in the sample by chromatography; and

(5) determining the relative amount of the capped and uncapped fragments in the sample by determining the relative peak areas of the capped and uncapped fragments, thereby quantifying the percentage of capped mRNA.

2. The method of claim 1 , wherein the capped mRNA has a structure of formula I:

wherein,

B is a nucleobase;

R 1 is selected from a halogen, OH, and OCH 3 ;

R 2 is selected from H, OH, and OCH 3 ;

R 3 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or void;

R 4 is NH 2 ;

R 5 is selected from OH, OCH 3 and a halogen;

n is 1, 2, or 3; and

M is a nucleotide of the mRNA.

3. The method of claim 2 , wherein the nucleobase is guanine.

4. The method of claim 1 , wherein the capped mRNA comprises a cap that is a m 7 G cap with a structure of formula II or an unmethylated cap with a structure of formula III:

wherein,

R 2 is H or CH 3 ;

R 4 is NH 2 ;

R 5 is OH or OCH 3 ;

R 6 is H or CH 3 ; and

M is a nucleotide of the mRNA; or

wherein M is a nucleotide of the mRNA.

5. The method of claim 1 , wherein step (4) further separates methylated and unmethylated capped RNA.

6. The method of claim 5 , wherein the method further comprises a step of quantitatively determining methylation percentage of the capped RNA.

7. The method of claim 6 , wherein the quantifying step is conducted before releasing an mRNA lot.

8. The method of claim 1 , wherein the DNA oligonucleotide is linked to one or more RNA nucleotides.

9. The method of claim 1 , wherein the sequence in the 5′ untranslated region of the mRNA is within 1 or 2 bases from the cap or uncapped penultimate base of mRNA.

10. The method of claim 1 , wherein the one or more nucleases comprise a nuclease that generates blunt-ended capped and uncapped fragments.

11. The method of claim 1 , wherein the mRNA sample is synthesized in vitro.

12. The method of claim 1 , wherein the one or more nucleases is RNase H.

Assignments (3)
CHANGE OF NAME Recorded May 20, 2019
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 049222/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2019
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 049154/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2019
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; DIAS, ANUSHA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 049127/0063 →